Fiche publication


Date publication

mai 2016

Journal

Thrombosis research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NGUYEN Philippe


Tous les auteurs :
Guillou S, Tamareille S, Giraud S, Poitevin G, Prunier-Mirebeau D, Nguyen P, Prunier F, Macchi L

Résumé

Fondaparinux (FDX) was demonstrated to be cardioprotective in a rat model of myocardial ischemia reperfusion. In this model, FDX reduced infarct size after 2h of reperfusion, involving the activation of the survivor activating factor enhancement (SAFE) pathway as early as 30min post-reperfusion. Our aim was to study if this cardioprotection could be explained by anti-inflammatory mechanisms and a protective effect on vessels.

Référence

Thromb. Res.. 2016 May;141:98-103